These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Clinical and genetic characteristics in patients with Huntington's disease from China. Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361 [TBL] [Abstract][Full Text] [Related]
27. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures. Reilmann R; Bohlen S; Kirsten F; Ringelstein EB; Lange HW Mov Disord; 2011 Oct; 26(12):2267-73. PubMed ID: 21661053 [TBL] [Abstract][Full Text] [Related]
28. Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT-HD. Long JD; Paulsen JS; Mov Disord; 2015 Oct; 30(12):1664-72. PubMed ID: 26340420 [TBL] [Abstract][Full Text] [Related]
29. Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning. Reedeker N; Van Der Mast RC; Giltay EJ; Van Duijn E; Roos RA Mov Disord; 2010 Aug; 25(11):1612-8. PubMed ID: 20629165 [TBL] [Abstract][Full Text] [Related]
30. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting. Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172 [TBL] [Abstract][Full Text] [Related]
31. Early cognitive deficits in Swedish gene carriers of Huntington's disease. Robins Wahlin TB; Lundin A; Dear K Neuropsychology; 2007 Jan; 21(1):31-44. PubMed ID: 17201528 [TBL] [Abstract][Full Text] [Related]
33. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Videnovic A; Bernard B; Fan W; Jaglin J; Leurgans S; Shannon KM Mov Disord; 2010 Feb; 25(3):401-4. PubMed ID: 20108371 [TBL] [Abstract][Full Text] [Related]
34. An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Vaccarino AL; Anderson K; Borowsky B; Duff K; Giuliano J; Guttman M; Ho AK; Orth M; Paulsen JS; Sills T; van Kammen DP; Evans KR; Mov Disord; 2011 Apr; 26(5):877-84. PubMed ID: 21370269 [TBL] [Abstract][Full Text] [Related]
35. Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing cognitive load. Wolf RC; Sambataro F; Vasic N; Schönfeldt-Lecuona C; Ecker D; Landwehrmeyer B Eur J Neurol; 2008 Nov; 15(11):1180-90. PubMed ID: 18754766 [TBL] [Abstract][Full Text] [Related]
36. Unified Huntington's disease rating scale for advanced patients: validation and follow-up study. Youssov K; Dolbeau G; Maison P; Boissé MF; Cleret de Langavant L; Roos RA; Bachoud-Lévi AC Mov Disord; 2013 Oct; 28(12):1717-23. PubMed ID: 24166899 [TBL] [Abstract][Full Text] [Related]
37. A double blind evaluation of cognitive decline in a Norwegian cohort of asymptomatic carriers of Huntington's disease. van Walsem MR; Sundet K; Retterstøl L; Sundseth Ø J Clin Exp Neuropsychol; 2010 Jul; 32(6):590-8. PubMed ID: 19916101 [TBL] [Abstract][Full Text] [Related]
38. Hypertension, Antihypertensive Use and the Delayed-Onset of Huntington's Disease. Steventon JJ; Rosser AE; Hart E; Murphy K Mov Disord; 2020 Jun; 35(6):937-946. PubMed ID: 32017180 [TBL] [Abstract][Full Text] [Related]
39. Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease. Hart EP; Dumas EM; Schoonderbeek A; Wolthuis SC; van Zwet EW; Roos RA Mov Disord; 2014 Mar; 29(3):320-6. PubMed ID: 24500841 [TBL] [Abstract][Full Text] [Related]
40. White matter connectivity reflects clinical and cognitive status in Huntington's disease. Poudel GR; Stout JC; Domínguez D JF; Salmon L; Churchyard A; Chua P; Georgiou-Karistianis N; Egan GF Neurobiol Dis; 2014 May; 65():180-7. PubMed ID: 24480090 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]